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Abstract Rapamycin has important roles in the modulation of regulatory T cells. We tried to expand CD4 + CD25 + regulatory T cells (Treg cells) from umbilical cord blood (CB) CD4-positive cells using interleukin (IL)-15 or IL-2 with transforming growth factor (TGF)-β and rapamycin. We were able to obtain more than 500-fold expansion of CD4 + CD25
+ cells from CB CD4 + cells using IL-15 and TGF-β with rapamycin. These expanded CD4 + CD25
+ cells expressed forkhead box P3 (FoxP3) mRNA at a level about 100-fold higher and could suppress allogeneic mixed lymphocyte culture (MLC) by more than 50%. Early after rapamycin stimulation, CB CD4 + cells showed increased expression of FoxP3 and a serine/threonine kinase Pim2 and sustained expression of negative phosphoinositide 3-kinase regulator phosphatase and tensin homolog deleted on chromosome 10 (PTEN) 
CD25
+ regulatory T cells (Treg cells) contribute to the suppression of allogeneic immune responses and prevent transplant rejection and graft-versus-host disease (GVHD) [1] [2] [3] . Cord blood contains naïve T cells and Treg precursor cells that can be expanded by several cytokines [4] [5] [6] [7] . We previously reported more than 50-fold expansion of CD4 + CD25 + regulatory T cells from cord blood CD4 +
+ cells using interleukin (IL)-15 and transforming growth factor (TGF)-β [8] . The serine/threonine protein kinase mammalian target of rapamycin (mTOR) has important roles in the activation of effector T cells and the function and proliferation of regulatory T cells. Blockade of mTOR by rapamycin inhibits T cell proliferation, and rapamycin is therefore used for prophylaxis of GVHD and graft rejection [9] . It has been shown that rapamycin selectively expands murine naturally occurring CD4 CD25 forkhead box P3 (FoxP3) T cells in vitro [10] and that it induces suppressor functions in conventional CD4 T cells [11] . Selective expansion and the survival and proliferation of naturally occurring regulatory T cells can be achieved by using rapamycin [12] . FoxP3 is indispensable for the differentiation of regulatory T cells [13] . The lipid phosphatase and tensin homolog deleted on chromosome 10 (PTEN) regulates the anergic response of Treg cells to IL-2 in vitro and Treg homeostasis in vivo [14] . The expression level of PTEN, a negative regulator of the phosphoinositide 3-kinase (PI3K)/Akt/mTOR pathway, remained high in Treg cells during stimulation [15] .
Pim2 is a serine/threonine kinase that can confer resistance to rapamycin. Pim2 regulates late cell cycle progression induced by IL-2 [16] . FoxP3 induces Pim2 expression in Treg cells, conferring a replicative advantage in cultures containing rapamycin [17] . Therefore, FoxP3, Pim2, and PTEN may have important roles in the expansion of Treg cells using rapamycin. IL-15 utilizes the beta and gamma chains of IL-2 receptor [18] . IL-15 has an anti-apoptotic effect and a preferential survival enhancing effect on cord blood T cells [19, 20] . Therefore, IL-15 may have a positive effect to induce Treg cells with rapamycin.
In this study, we tried to expand Treg cells from cord blood CD4
+ cells using the common γ-chain cytokine IL-15 and TGF-β with or without rapamycin, and we compared the effect of IL-15 and IL-2 in order to develop a potential strategy for cell therapy to control GVHD and graft rejection after allogeneic stem cell transplantation. Also, we analyzed FoxP3, Pim2, and PTEN expression during expansion of Treg cells using rapamycin in order to reveal the mechanism of proliferation of Treg cells in the presence of the T cell growth inhibitor rapamycin.
Materials and methods

Isolation of CD4
+ cells from cord blood and culture CD4-positive cells were isolated from umbilical cord blood cells (Hokkaido Cord Blood Bank, Sapporo, Japan) by positive selection using magnetic cell sorting (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). Fluorescenceactivated cell sorting (FACS) analysis showed that cells were routinely more than 90% CD4-positive for the CD4-positive fraction. CD4 + cells (0.2×10 6 /mL) were cultured with 10 μL of anti-CD3/CD28 mAb-coated dynabeads (Dynal Biotech, Lake Success, NY, USA) and IL-2 (5 ng/mL) or IL-15 (5 ng/mL) with or without TGF-β (1 ng/mL; R&D Systems, Minneapolis, MN, USA) in RPMI-1640 with 10% fetal calf serum in 24-well plates in the presence or absence of rapamycin (Sigma-Aldrich; 0.5-1.0 nM). Cell cultures were split approximately one fourth after 3 days of culture, and fresh medium, cytokines, and anti-CD3/CD28 dynabeads were added. 
Real-time PCR
Total RNA was prepared using a QIAamp RNA Blood Mini Kit (QIAGEN), and cDNA was synthesized from 1.2 μg total RNA using a TaKaRa RNA PCR Kit(AMV) Ver.3.0 following the instructions of the manufacturer (TAKARA, Shiga, Japan). Assays-on-Demand™ Gene Expression products for FoxP3, Pim2, and PTEN were obtained from Applied Biosystems. Glyceraldehyde-3-phosphate dehydrogenase was used as an endogenous control. Relative quantification assays for gene expression were performed using an Applied Biosystems 7300 Real-time PCR system (Applied Biosystems). 
Results
Expansion of CD4
CD25
+ cells expanded without rapamycin. However, the expression level of Pim2 was not so elevated, and the expression level of PTEN was downregulated after 8 days of stimulation even using rapamycin. IL-2 stimulation showed almost the same tendency for induction of these genes, though slightly lower efficiency for induction of FoxP3 on day 8 by stimulation with rapamycin was noted (93.3±15.1 vs 60.2±47.5, P=0.068; Table 8 ). 
Discussion
Treg cells have an important role in the regulation of allogeneic immune responses after allogeneic stem cell transplantation. Rapamycin inhibits the mTOR pathway and has an impact on expansion and activity of Treg cells. Treg cells are resistant to rapamycin-induced apoptosis and thus selectively expand in the presence of rapamycin [9] . IL-2 has been used for the expansion of cytotoxic CD8 cells and also Treg cells. IL-15 enhances T cell and NK cell proliferation by using the β-and γ-chains of the IL-2 receptor [21] . It has been reported that IL-15 enhanced in vitro T cell survival and effector function after autologous stem cell transplantation [22] . Also, IL-15 enhanced TNF-α and IL-10 production during cord blood alloreactivity but failed to enhance allospecific proliferation [23] . It has been reported that peripheral CD4 + CD25 − naive T cells are converted to CD4 + CD25 + regulatory T cells by TGF-β induction of transcription factor FoxP3 and that they develop suppressive activity [5, 24] . We previously reported expansion of CD4 +
CD25
+ regulatory T cells from cord blood CD4 +
+ cells using IL-15 [8] . Therefore, there is a possibility that IL-15, TGF-β, and rapamycin can be used to induce the expansion of Treg cells derived from cord blood. In this study, CD4 + CD25 + cells could be expanded efficiently by more than 500-fold from cord blood CD4 + cells using the common γ-chain cytokine IL-15, TGF-β, and rapamycin. Addition of rapamycin to the stimulation of IL-15 and TGF-β helped to induce selective expansion of CD25 +
FoxP3
+ cells (FoxP3/CD4 ratio was 0.371 without rapamycin vs 0.771 with rapamycin), though the number of CD4 + CD25 + cells was relatively small (6.368±1.071 without rapamycin vs 5.001±1.207 with rapamycin). Also, these expanded CD4 + CD25 + cells could suppress third-party MLR, and these CD25 + CD4
+ cells were anergic against allogeneic antigens and could not response allogeneic third-party stimulators. These results indicate that stimulation with anti-CD3/CD28 mAb-coated dynabeads and IL-15 plus TGF-β with rapamycin may be a powerful inducer of selective expansion of Treg cells with 
CD25
+ cells and for FoxP3 expression, and IL-15 also showed significantly higher efficacy for inhibition of MLC.
It has been reported that rapamycin promoted the outgrowth of Treg cells [10] [11] [12] ; however, Hippen et al. [25] reported that rapamycin had no advantage for increasing the overall number of Treg cells from cord blood CD4 +
+ cells in expansion culture using IL-2 and anti-CD3/CD28 mAb-coated dynabeads. Therefore, rapamycin-mediated enrichment of Treg cells may be due to the selective expansion of conventional CD4 + cells in cord blood.
However, the mechanism of Treg cell-specific proliferation in the presence of rapamycin, which has a potent immunosuppressive action to inhibit growth factor-induced T cell proliferation, is not clear. The IL-2 receptor and signal transducer and activator of transcription 5 (STAT5) pathway are essential for activity of Treg cells [26] [27] [28] . Pim2 kinase is involved in conferring resistance of Treg cells to rapamycin-mediated inhibition when STAT5-signaling cytokines are present [17] . IL-15 receptor contains IL-2 receptor β and uses the STAT5 signal pathway [29] . In this study, we investigated the expression levels of FoxP3, Pim2, and PTEN during cord blood CD4 + cell culture with rapamycin to clarify the mechanism of Treg cell proliferation in the presence of the T cell growth inhibitor rapamycin. Cord blood CD4 + cells cultured with rapamycin showed an increased expression level of serine/ threonine protein kinase Pim2 early after stimulation and a decreased mRNA expression level of the negative PI3K regulator PTEN at late phase of culture. Increased expression of Pim2 by IL-15 and TGF-β with rapamycin may be able to confer rapamycin resistance for growth of Treg cells. Also, decreased expression of PTEN may give an advantage to Treg cells for proliferation. Taken together, the results suggest that increased expression of Pim2 at the early phase and decreased expression of PTEN at the late phase compensate for AKT inactivity and promote cell cycle progression of Treg cells derived from cord blood. Therefore, rapamycin may be useful for expansion of Treg cells. IL-2 stimulation showed almost the same tendency Rp rapamycin *P<0.01 (significant differences were found in the values after stimulation with Rp and IL-2/TGF-β and other conditions) Rp rapamycin *P<0.01; **P<0.05 (significant differences were found in the values after stimulation with Rp + IL-15 + TGF-β and other cytokines); ***P<0.05 (significant differences were found in the values after stimulation with for induction of these genes; however, IL-15 had a little higher efficiency for induction of FoxP3 on day 8. Therefore, IL-15 is not less useful than IL-2 for expansion of Treg cells.
Regulatory T cells play a vital role in downregulating GVHD and are critically important for the establishment of active dominant tolerance to both allo-and self-major histocompatibility complex antigens [30] . Also, one of the mechanisms involved in tolerance is the suppression of graft-specific alloreactive T cells, which largely mediate graft rejection, by Treg cells. The ability to isolate and expand Treg cells with immune suppressive activity will enable new forms of adoptive immunotherapy for GVHD after allogeneic stem cell transplantation, rejection after organ transplantation, and autoimmune disorders [31] [32] [33] [34] . + Treg cells enrichment from cryopreserved third cord blood unit followed by expansion culture including anti-CD3/anti-CD28 antibody-coated beads and IL-2 [35] . At first, enrichment of CD25 + cells was accomplished by positive selection with anti-CD25 magnetic beads and then expanded Treg cells using anti-CD3/ anti-CD28 antibody-coated beads and IL-2 for 18 days. 5 third cord blood unit derived Treg cells/kg after double cord blood transplantation. Compared to identically treated 108 historical control patients without Treg cells, there was a reduced incidence of grades II-IV acute GVHD without deleterious effect on risks of infection, relapse, or early mortality in Treg cells treated patients. Therefore, allogeneic Treg cells expanded from cord blood may have clinical effect for preventing GVHD. In this study, we showed that the combination of the common γ-chain cytokine IL-15, TGF-β, and rapamycin with anti-CD3/ anti-CD28 antibody-coated beads may be an effective means for expanding Treg cells from cord blood CD4 + cells with high expansion efficacy (mean 706-folds) and high purity (mean 98.4% CD4 + CD25 + ) for 8 days culture. Therefore, ex vivo expanded Treg cells under good manufacturing practice standard condition from allogeneic cord blood by our method may enable adaptive Treg cell therapy for the prevention and treatment of GVHD after allogeneic stem cell transplantation. Also, there is a possibility to use these expanded Treg cells for the treatment of rejection after organ transplantation.
